Brain Research Center Den Bosch B.V.

Running trials

• Recruiting

  Study to Test Effects and Safety of RO7568282 in Early Parkinson's Disease

  NCT07781644· Phase 2· Source

• Not yet recruiting

  A Study of Brenipatide in Participants With Major Depressive Disorder

  NCT07928245· Phase 2· Source

• Recruiting

  A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight

  NCT07564414· Phase 3· Source

• Active, not recruiting

  AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss

  NCT07503210· Phase 3· Source

• Recruiting

  A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL628 in Participants With Early Alzheimer's Disease

  NCT07328451· Phase 1· Source

• Active, not recruiting

  A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

  NCT07170150· Phase 3· Source

• Recruiting

  A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease

  NCT07214727· Phase 1· Source

• Recruiting

  EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

  NCT07064473· Phase 3· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)

  NCT06976203· Phase 3· Source

• Recruiting

  A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)

  NCT07033494· Phase 2· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease

  NCT06976216· Phase 3· Source

• Recruiting

  A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease

  NCT06976268· Phase 2/3· Source

• Recruiting

  Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin

  NCT06677060· Phase 3· Source

• Recruiting

  A study to test the biological properties of RO7568282 and whether it is safe in healthy participants and participants with Parkinson’s disease.

  2024-511110-21-00· Phase 1· Source

• Active, not recruiting

  Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD)

  NCT05531526· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Alzheimer disease5 recruiting
• Parkinson disease3 recruiting
• Depression1 recruiting
• Heart failure1 recruiting
• High blood pressure1 recruiting
• Type 2 diabetes1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A clinical trial to learn about the effects of VHB937 in people with Alzheimer's disease

  2024-516966-12-00· Phase 2· Source

• Completed

  GSK4527226 Open-label Extension Study in Patients with Early Alzheimer's Disease.

  2025-521107-42-00· Phase 2· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

  NCT07174310· Phase 3· Source

• Recruiting

  Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

  NCT06966401· Phase 3· Source

• Completed

  A Phase 2 Randomized, Placebo-Controlled, Double-Blind, Parallel-group Study to Evaluate the Efficacy and Safety of MK-1167 as Adjunctive Therapy in Participants with Mild to Moderate Alzheimer’s Disease Dementia

  2024-515539-31-00· Phase 2· Source

• Completed

  Characterization of Immune Response in Participants from a Posdinemab Study

  2024-514634-20-00· Phase 1· Source

• Completed

  EFFICACY AND SAFETY OF GSK4527226 [AL101] IN PATIENTS WITH EARLY ALZHEIMER’S DISEASE

  NCT06079190· Phase 2· Source

• Completed

  Study to Assess Safety and Efficacy of PRI-002 in Patients With MCI to Mild Dementia Due to Alzheimer's Disease (AD)

  NCT06182085· Phase 2· Source

• Completed

  Randomised, double-blind, placebo-controlled study to assess safety and efficacy of PRI-002 in patients with MCI or mild dementia due to Alzheimer’s disease (AD)

  2022-503148-41-00· Phase 2· Source

• Completed

  A Phase 2b Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients with Dementia with Lewy Bodies (DLB)

  2023-504373-20-00· Phase 2· Source

• Completed

  GV1001 Subcutaneous(SC) for the Treatment of Mild to Moderate Alzheimer's Disease (AD)

  NCT05189210· Phase 2· Source

• Completed

  A Study to Test the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Patients With Mild Cognitive Impairment or Mild Alzheimer's Disease (AD)

  NCT04867616· Phase 2· Source

• Completed

  A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)

  NCT04777409· Phase 3· Source

• Completed

  A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)

  NCT04777396· Phase 3· Source

• Completed

  Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type.

  NCT04464564· Phase 3· Source

• Completed

  A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study with a Long-Term Extension Treatment Period to Assess the Efficacy and Safety of JNJ-63733657, an Anti-tau Monoclonal Antibody, in Participants with Early Alzheimer’s Disease

  2022-501188-42-00· Phase 2· Source

• Completed

  A study to assess how ALZ-801 affects laboratory tests and symptoms of Alzheimer's disease in patients who have a specific genotype (APOE4).

  2024-515858-25-00· Phase 2· Source

• Active, not recruiting

  A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)

  NCT04437511· Phase 3· Source